The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

LI.ak

Cardiotoxicity

Publications

de la Brassinne Bonardeaux O, Born B, Moonen M, Lancellotti P

Mild Cardiotoxicity and Continued Trastuzumab Treatment in the Context of HER2-Positive Breast Cancer.

Journal of clinical medicine 2023 Oct 24;12; — 2023 Oct 24

Calvillo-Argüelles O, Abdel-Qadir H, Suntheralingam S, Michalowska M, Amir E, Thavendiranathan P

Trastuzumab-Related Cardiotoxicity and Cardiac Care in Patients With HER2 Positive Metastatic Breast Cancer.

The American journal of cardiology 2020 Jan 27;; — 2020 Jan 27

Martinello R, Becco P, Vici P, Airoldi M, Del Mastro L, Garrone O, Barone C, Pizzuti L, D'Alonzo A, Bellini E, Milani A, Bonzano A, Montemurro F

Trastuzumab-related cardiotoxicity in patients with nonlimiting cardiac comorbidity.

The breast journal 2019 May;25;444-449 — 2019 May — 444-449

Mohan N, Jiang J, Dokmanovic M, Wu WJ

Trastuzumab-mediated cardiotoxicity: current understanding, challenges, and frontiers.

Antibody therapeutics 2018 Aug 31;1;13-17 — 2018 Aug 31 — 13-17

Mantarro S, Rossi M, Bonifazi M, D'Amico R, Blandizzi C, La Vecchia C, Negri E, Moja L

Risk of severe cardiotoxicity following treatment with trastuzumab: a meta-analysis of randomized and cohort studies of 29,000 women with breast cancer.

Internal and emergency medicine 2016 Feb;11;123-40 — 2016 Feb — 123-40

Pistilli B, Marcellusi A, Latini L, Accardi R, Ferretti B, Benedetti G

Cardiotoxicity related to long-term trastuzumab therapy in metastatic breast cancer: the potential role of treatment duration and cardiac risk factors.

The breast journal 2015 May-Jun;21;318-21 — 2015 May-Jun — 318-21

Ayres LR, de Almeida Campos MS, de Oliveira Gozzo T, Martinez EZ, Ungari AQ, de Andrade JM, Pereira LR

Trastuzumab induced cardiotoxicity in HER2 positive breast cancer patients attended in a tertiary hospital.

International journal of clinical pharmacy 2015 Apr;37;365-72 — 2015 Apr — 365-72

Farolfi A, Melegari E, Aquilina M, Scarpi E, Ibrahim T, Maltoni R, Sarti S, Cecconetto L, Pietri E, Ferrario C, Fedeli A, Faedi M, Nanni O, Frassineti GL, Amadori D, Rocca A

Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factors.

Heart (British Cardiac Society) 2013 May;99;634-9 — 2013 May — 634-9

Fedele C, Riccio G, Coppola C, Barbieri A, Monti MG, Arra C, Tocchetti CG, D'Alessio G, Maurea N, De Lorenzo C

Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitors.

Breast cancer research and treatment 2012 Jun;133;511-21 — 2012 Jun — 511-21

Guglin M, Hartlage G, Reynolds C, Chen R, Patel V

Trastuzumab-induced cardiomyopathy: not as benign as it looks? A retrospective study.

Journal of cardiac failure 2009 Oct;15;651-7 — 2009 Oct — 651-7